Cover Image

Safety Proﬁle of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study

Safety data for secukinumab in patients with psoriasis and viral hepatitis are lacking. The aim of this study is to investigate the risk of reactivation of hepatitis B virus (HBV)/hepatitis C virus (HCV) in patients with psoriasis who are receiving secukinumab therapy. This multicentre study screene...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hsien-Yi Chiu (Author), Rosaline Chung-Yee Hui (Author), Yu-Huei Huang (Author), Ruey-Yun Huang (Author), Kai-Lung Chen (Author), Ya-Chu Tsai (Author), Po-Ju Lai (Author), Ting-Shun Wang (Author), Tsen-Fang Tsai (Author)
Format:	Book
Published:	Medical Journals Sweden, 2018-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement
by: Tzong-Yun Ger, et al.
Published: (2019)

Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single-center experience
by: Ting-Shun Wang, et al.
Published: (2017)

Treatment response in patients with moderate-to-severe psoriasis who had inadequate response to prior secukinumab
by: Tai-Siang Chiu, et al.
Published: (2019)

Patient's perception and importance of clear/almost clear skin in moderate-to-severe plaque psoriasis: Results of clear about psoriasis survey in Taiwan
by: Yu-Huei Huang, et al.
Published: (2019)

Long-term effectiveness and safety of ixekizumab in the treatment of 14 patients with a history of chronic erythrodermic psoriasis who failed prior secukinumab: A bicentric retrospective study
by: Yang Lo, et al.
Published: (2021)

Psoriasis in Taiwan: From epidemiology to new treatments
by: Hsien-Yi Chiu, et al.
Published: (2018)

Sparing of injection sites in patients with extensive psoriasis treated with various biologics
by: Ya-Chu Tsai, et al.
Published: (2019)

Profile of secukinumab in the treatment of psoriasis: current perspectives
by: Roman M, et al.
Published: (2015)

T helper type 17 in psoriasis: From basic immunology to clinical practice
by: Hsien-Yi Chiu, et al.
Published: (2012)

Practical experience of ustekinumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to previous tumor necrosis factor blockers
by: Tzu-Chang Wang, et al.
Published: (2015)

Initial Results of Secukinumab Drug Survival in Patients with Psoriasis: A Multicentre Daily Practice Cohort Study
by: Juul M.P.A. van den Reek, et al.
Published: (2018)

Prevalence, clinical features and treatment pattern of patients with concurrent diagnoses of rheumatoid arthritis and psoriatic disease: results of a 14-year retrospective study in a tertiary referral center
by: Kai-Lung Chen, et al.
Published: (2019)

Secukinumab in generalized pustular psoriasis
by: Shraddha Madanagobalane
Published: (2018)

Secukinumab Therapy in Psoriasis Management
by: Ira Yunita, et al.
Published: (2022)

Safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept
by: Ting-Shun Wang, et al.
Published: (2013)

Reactivation of Epstein-Barr virus and cytomegalovirus in patients with psoriasis after ustekinumab treatment
by: Chang-Yu Hsieh, et al.
Published: (2020)

The significance of secukinumab in the treatment of plaque psoriasis
by: Marta Kasprowicz-Furmańczyk, et al.
Published: (2022)

Efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis
by: Zhanhan TANG, et al.
Published: (2023)

Verrucous inverse psoriasis: A novel variant of psoriasis
by: Hsuan-An Su, et al.
Published: (2023)

Changes in metabolic parameters in psoriatic patients treated with secukinumab
by: Hsuan Ning Wang, et al.
Published: (2020)

Long-term control of refractory Schnitzler syndrome with anakinra: a case report
by: Hsien-Yi Chiu, et al.
Published: (2010)

Itraconazole in the Treatment of Nonfungal Cutaneous Diseases: A Review
by: Ya-Chu Tsai, et al.
Published: (2019)

Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
by: Alessio Gambardella
Published: (2019)

Secukinumab in psoriasis: A single-center experience
by: Esra Ağaoğlu, et al.
Published: (2021)

Secukinumab-induced paradoxical palmoplantar pustular psoriasis
by: Yıldız Gürsel Ürün, et al.
Published: (2022)

Secukinumab in the treatment of psoriasis: patient selection and perspectives
by: Yang EJ, et al.
Published: (2018)

Promising results with secukinumab in refractory pediatric psoriasis
by: Sukriti Baveja, et al.
Published: (2020)

Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience
by: Yi-Wei Huang, et al.
Published: (2019)

Effectiveness and safety of adalimumab in treating moderate to severe psoriasis patients with psoriatic arthritis in Taiwan
by: Pei-Han Kao, et al.
Published: (2015)

Secukinumab for Psoriasis in Obese Patients: Minireview and Clinical Experience
by: Rossana Tiberio, et al.
Published: (2019)

Alcohol consumption, aldehyde dehydrogenase 2 gene rs671 polymorphism, and psoriasis in Taiwan
by: Ya-Ching Chang, et al.
Published: (2022)

Papular xanthoma with destructive arthritis (a variant of multicentric reticulohistiocytosis): Reports of two cases
by: Chi-Zai Sin, et al.
Published: (2019)

Response of Psoriasis with Systemic Lupus Erythematosus to Secukinumab: A Case Report and Review of the Literature
by: Dai B, et al.
Published: (2023)

Psoriasis flare following ChAdOx1-S/nCoV-19 vaccination in patients with psoriasis under biologic treatment
by: Jen-Ping Chao, et al.
Published: (2021)

A lack of association between genetic polymorphisms in beta-defensins and susceptibility of psoriasis in Taiwanese: A case-control study
by: Yu-Jui Hsieh, et al.
Published: (2016)

Correlation of thiopurine methyltransferase and inosine triphosphate pyrophosphatase polymorphisms and adverse effects induced by azathioprine treatment in Taiwanese dermatology patients
by: Ting-Shun Wang, et al.
Published: (2014)

Atopic Dermatitis as a Paradoxical Effect of Secukinumab for the Treatment of Psoriasis
by: Eduardo V. Mendes Roncada, et al.
Published: (2021)

Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report
by: Lu X, et al.
Published: (2023)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
by: Simone Ribero, et al.
Published: (2019)

Paradoxical pustular psoriasis in a patient with spondyloarthritis treated with secukinumab
by: Daniela Anghel, et al.
Published: (2023)